In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Alsius Medical Corp.

Division of Asahi Kasei Corp.
www.alsius.com

Latest From Alsius Medical Corp.

Philips buys Innercool: The Ice Age Cometh

As part of a bid to connect the dots between its own product offerings, Philips Healthcare acquired InnerCool Therapies, maker of surface and endovascular cooling devices for the management of cardiac patients. InnerCool fits into the company's broader "care cycle" strategy, the point of which is to provide a continuum of care to patients in the diseases Philips serves. Specifically, Philips' strategy is to connect diverse care settings to its product markets, in this case, cardiac resuscitation. The combination marks a change in how sudden cardiac arrest is regarded, from an isolated episode focused on a stopped heart to a larger strategy of patient management.
Medical Device

Best of the Blog: Start-Up April 2008

"Best of the Blog" is a monthly column highlighting the best of our free online content at www.windhover.com/blog. In May: cell therapy for Parkinson's, the difficulty of SPACs, Roche buys Piramed, and another boost for microRNA.

Dynogen Tries the SPAC Alternative

Special Purpose Acquisition Companies--SPACs--are springing up in the wide spaces abandoned by IPOs-- and they look tempting for those biotechs who can't get to a Big Pharma deal without first raising a big slug of money. That's Dynogen's problem: no deal until it can show solid efficacy from its two lead compounds. With no IPO or big private financing likely, Dynogen turned to a SPAC, a public shell company created to find a Dynogen-like opportunity. But SPAC investors can extract a big price for their cooperation-particularly in the current risk-averse public market.
BioPharmaceutical Business Strategies

Business & Technology Briefs (08/2007)

Brief summaries of recent product and company developments in the device industry, including the demise of GE's proposed $8 billion acquisition of Abbott Diagnosticss, the Cytyc/Hologic merger, and Alsius' SPAC merger.
See All

Company Information

  • Industry
  • Medical Devices
    • Implantable Devices
    • Monitoring Equipment & Devices
    • Surgical Equipment & Devices
  • Therapeutic Areas
  • Cardiovascular
  • Neurology, Nervous System
  • Alias(es)
  • Neuroperfusion Inc.
  • Ithaka Acquisition Corp.
  • Alsius Corp.
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Asahi Kasei Corp.
  • Senior Management
  • William Worthen, Pres. & CEO
    Greg Tibbitts, CFO
    Suzanne Winter, VP, WW Sales & Mktg.
    Lynn Shimada, VP, R&D
  • Contact Info
  • Alsius Medical Corp.
    Phone: (949) 453-0150
    15770 Laguna Canyon Rd.
    Ste. 150
    Irvine, CA 92618
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register